CSL suffered its worst loss in months, while JB Hi-Fi, Pro Medicus and Audinate hit record highs. -AAP Image
A failed drug trial by Australia's third-largest company has helped drag the ASX into the red at the start of the week's trading.
Hold tight - we’re checking permissions before loading more content
The benchmark S&P/ASX200 index finished Monday down 29.9 points, or 0.39 per cent, to 7,614.9, while the broader All Ordinaries dropped 24.4 points, or 0.31 per cent, to 7,860.3.
CSL suffered its worst loss in four months, falling 4.8 per cent to $290.24, and causing a 21.3-point drop in the ASX200, making it responsible for more than 70 per cent of the day's losses for the index.
The blood products giant announced Monday that a plasma-derived treatment it had spent two decades and almost $1 billion developing did not appear to prevent secondary heart attacks, as CSL had hoped.
The Australian dollar was buying 65.20 US cents, from 64.98 US cents at Friday's ASX close.
7°C